Multifunctional abdominal aortic aneurysm targeting nanoparticle as well as preparation method and application thereof

By modifying polyphenol oxidative self-polymerized nanoparticles with the targeting ligand cRGD and adsorbing doxycycline, the nanoparticles are targetedly enriched at the AAA site and the drug is released in a directed manner. This solves the problems of non-specific distribution and side effects of drugs in the treatment of AAA in the prior art, and achieves multiple synergistic effects, effectively controlling the expansion and rupture of AAA.

CN119033960AActive Publication Date: 2024-11-29CENT SOUTH UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411207867.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-29
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

There is a lack of effective drug treatments to control the expansion and rupture of abdominal aortic aneurysms (AAA) in the current technology. Furthermore, existing drugs such as doxycycline have non-specific distribution and side effects, making them difficult to target the complex pathological changes of AAA and resulting in poor treatment effects.

Method used

Using polyphenol oxidized self-polymerized nanoparticles as a carrier, the nanoparticles are targeted and enriched at the AAA lesion site and the drug is released in a directed manner by modifying the surface with the targeting ligand cRGD and adsorbing doxycycline. Combined with the antioxidant effect of the nanocarrier, the nanoparticles exert multiple activities such as anti-inflammatory, antioxidant and MMP inhibition.

Benefits of technology

It significantly improved the drug accumulation efficiency at the AAA site, reduced the hepatotoxicity and nephrotoxicity of doxycycline, achieved multiple synergistic effects, effectively treated AAA, and improved biosafety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033960A_ABST
    Figure CN119033960A_ABST
Patent Text Reader

Abstract

The invention provides a multifunctional abdominal aortic aneurysm targeting nanoparticle and a preparation method and application thereof, and belongs to the field of nano biological medicine.The multifunctional abdominal aortic aneurysm targeting nanoparticle is prepared by taking polyphenol oxidation self-polymerization nanoparticles as a carrier, entrapping doxycycline and modifying a targeting ligand cRGD on the surface of the nano carrier. Neonatal vessels in a middle membrane and an outer membrane at an AAA part are beneficial to accumulation of nanoparticles in aneurysm, and a highly expressed integrin alpha v3beta receptor on the surface of a lesion cell membrane can recognize cRGD with high affinity, so that targeted endocytosis of the nanoparticles is mediated. After intravenous injection, the nanoparticles can be effectively enriched at a focus position and realize long-acting retention, and release DC in response to a high ROS level in a tumor microenvironment, the drug is quickly released and takes effect, the non-specific toxic and side effects of the drug are reduced, and the free radical scavenging ability of the nanoparticles can be cooperated with the activity of the DC, so that the drug delivery effect is improved. AAA is treated through multiple mechanisms of resisting inflammation, resisting oxidation, promoting macrophage repolarization, resisting apoptosis and calcification, inhibiting MMPs and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of nano-biomedicine, and specifically relates to multifunctional nanoparticles targeting abdominal aortic aneurysm and a preparation method and application thereof. Background Art

[0002] Abdominal aortic aneurysm (AAA) is a progressive, life-threatening vascular disease, but there is currently no effective drug control. Aneurysms with larger or irregular bodies have a very high risk of rupture, and once ruptured, the mortality rate is greater than 80%. With the aging of the population and the increase in the incidence of hypertension, the incidence and mortality of AAA are increasing year by year. Surgical intervention is currently the only effective method for treating AAA clinically. For AAA that does not meet the surgical indications (usually refers to a tumor larger than 3cm and smaller than 5.5cm), surgery is not possible, and patients are usually advised to monitor tumor changes regularly. However, small AAAs also have the risk of rupture, and regular monitoring requires angiography, which leads to the risk of liver and kidney damage. Therefore, it is imperative to develop effective drugs that can reduce AAA expansion and prevent AAA rupture.

[0003] The occurrence and development of AAA is associated with a series of pathological changes, including inflammatory cell infiltration, increased levels of matrix metalloproteinases (MMPs), excessive production of reactive oxygen species, intimal and medial calcification, neovascularization, apoptosis, vascular smooth muscle cell (VSMC) damage, and degeneration of the aortic elastic lamina. Therefore, the development of corresponding regulatory drugs targeting the pathological changes in the AAA site is a hot topic in current research.

[0004] Although doxycycline (DC) has a good inhibitory effect on MMPS and has achieved promising results in preclinical studies, it has not provided beneficial effects in clinical trials. In addition, due to the nonspecific distribution of DC, adverse reactions usually occur after administration. In addition, poor water solubility limits the clinical application of DC. More importantly, doxycycline has a single mechanism of action, which makes it difficult to target complex AAA pathological changes and achieve multidimensional disease treatment, resulting in poor therapeutic effects. Therefore, innovative drug delivery strategies are urgently needed to reduce the side effects of DC while enhancing its therapeutic effects to promote clinical transformation. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a multifunctional nanoparticle targeting abdominal aortic aneurysm and its preparation method and application. The carrier is polyphenol oxidized self-polymerized nanoparticles, and through the surface adsorption of doxycycline, through the modification of PEG-cRGD, the enrichment of nanoparticles in AAA lesions can be increased by 5 times, and targeted delivery can be achieved by recognizing the integrin αν3β receptor highly expressed on the lesion cell membrane. The nano drug can release doxycycline under the triggering of high levels of ROS in the local AAA, and achieve synergy with the powerful antioxidant effect of the nanocarrier itself, thereby exerting multiple activities such as anti-inflammatory, antioxidant and inhibition of MMPs, and achieving the treatment of AAA. At the same time, through the delivery of nanoparticle carriers, the hepato-renal toxicity induced by doxycycline can be significantly reduced, showing good biosafety.

[0006] To achieve the above objectives, the present scheme first provides a nanoparticle with the function of targeting abdominal aortic aneurysm, wherein the nanoparticle comprises polyphenol oxidation self-polymerized nanoparticles, doxycycline and a targeting ligand cRGD. The polyphenol oxidation self-polymerized nanoparticles are used as carriers, the surface of which is firstly modified with the targeting ligand cRGD, and then doxycycline is adsorbed on the surface.

[0007] Based on a general inventive concept, the present invention also provides a method for preparing multifunctional nanoparticles targeting abdominal aortic aneurysm, comprising the following steps:

[0008] S1. Preparation of carrier polyphenol oxidized self-polymerized nanoparticles: dissolving epigallocatechin gallate in a buffer solution of pH 7.4-8.5, stirring in a water bath at room temperature to obtain a mixed solution of epigallocatechin gallate, then dropping a divalent metal manganese ion solution, keeping the mixture in a water bath at a constant temperature, stirring vigorously, and then centrifuging to collect the precipitate, washing the precipitate with a buffer solution, and re-dissolving the precipitate by ultrasonication to obtain polyphenol oxidized self-polymerized nanoparticles;

[0009] S2, modifying the targeting ligand cRGD: adding thiol-polyethylene glycol-cyclic arginine-glycine-aspartic acid to the system prepared in S1 and stirring in a constant temperature water bath to construct the targeting ligand cRGD-polyphenol oxidized self-polymerized nanoparticles;

[0010] S3. Adsorption of doxycycline: Add doxycycline to the system prepared in S2 and stir in a constant temperature water bath to obtain multifunctional nanoparticles targeting abdominal aortic aneurysm.

[0011] Preferably, the buffer in step S1 is HEPES buffer, and the final concentration of the HEPES buffer is 10-15 mM; the stirring time in a water bath at room temperature is 1 min, the centrifugal speed is 16,000 rpm, and the centrifugal time is 20 min.

[0012] Preferably, in step S1, the molar ratio of epigallocatechin gallate to divalent metal manganese ion is 1:5 to 5:1.

[0013] Preferably, the metal manganese ion solution in step S1 is a MnCl2 solution, the final concentration of the metal manganese ions after dropwise addition is 0.5-12.5 mM, the temperature of the constant temperature water bath is 25°C-35°C, and the time of the vigorous stirring is 0.5-12 h.

[0014] Preferably, the molar ratio of the thiol-polyethylene glycol-cyclic arginine-glycine-aspartic acid to doxycycline is 1:4.5.

[0015] Preferably, the stirring temperature of the constant temperature water bath in step S2 is 37° C., and the stirring time of the constant temperature water bath is 2 h. The stirring temperature of the constant temperature water bath in step S3 is 37° C., and the stirring time of the constant temperature water bath is 2 h.

[0016] Based on a general inventive concept, the present invention also provides a multifunctional nanoparticle targeting abdominal aortic aneurysm for use in a drug for inhibiting the progression of abdominal aortic aneurysm.

[0017] The mechanism of the nanoparticles prepared in this scheme to inhibit abdominal aortic aneurysm is as follows:

[0018] Mechanism Figure 1 As shown in the results, the new blood vessels in the media and adventitia of the AAA site contribute to the accumulation of nanoparticles in the aneurysm, and the integrin αν3β receptor highly expressed on the surface of the lesion cells (including VSMC and macrophages) can recognize cRGD with high affinity, thereby mediating the targeted internalization of nanoparticles. After intravenous injection, the nanoparticles can be effectively enriched in the AAA site and achieve long-term retention, and release DC in response to the high ROS level in the AAA microenvironment, so that the drug is released quickly and its nonspecific toxic side effects are reduced. The free radical scavenging ability of the nanoparticles can cooperate with the activity of DCs, and it has been confirmed at the cell and animal levels that the nanodelivery system treats AAA through multiple mechanisms such as anti-inflammatory, anti-oxidation and inhibition of MMPs.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] (1) The nanoparticle carrier prepared in this scheme is a polyphenol oxidized self-polymerized nanoparticle, and doxycycline is adsorbed on the surface. Through PEG-cRGD modification, the enrichment of nanoparticles in AAA lesions can be increased by 5 times, and targeted delivery can be achieved by recognizing the integrin αν3β receptor highly expressed on the membrane of diseased cells.

[0021] (2) The nanoparticles prepared in this scheme can release doxycycline under the triggering of high levels of ROS in the local area of ​​AAA, and synergize with the powerful antioxidant effect of the nanocarrier itself, thereby exerting multiple activities such as anti-inflammation, anti-oxidation, promotion of macrophage repolarization, anti-cell apoptosis and calcification, and inhibition of MMPs, thereby achieving the treatment of AAA.

[0022] (3) Delivery via nanoparticle carriers can significantly reduce doxycycline-induced hepatotoxicity and renal toxicity, demonstrating good biosafety. This study provides a potential targeted nanoparticle drug for the treatment of aneurysms and also provides a design reference for the development of targeted drugs for other vascular diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 This is a working mechanism diagram of the multifunctional nanoparticles targeting abdominal aortic aneurysm prepared in Example 1;

[0025] Figure 2 are the characteristics of the nanoparticles in Experimental Example 1, A is a schematic diagram of the synthesis of cRGD-TPNs, B is a particle size diagram of TPNs, cRGD-TPNs and cRGD-TPNs / DC NPs, C is a potential diagram of TPNs, cRGD-TPNs and cRGD-TPNs / DC NPs; D is a UV-vis absorption spectrum to detect the concentration of thiol groups; E is a TEM image and an elemental scan of cRGD-TPNs; F is a schematic diagram of the synthesis of cRGD-TPNs / DC; G is the encapsulation efficiency of cRGD-TPNs / DC at different DC feed concentrations; H is a TEM image and an elemental scan of cRGD-TPNs / DC; I is the colloidal stability of cRGD-TPNs / DC in different media; J is the drug release of cRGD-TPNs / DC under different conditions;

[0026] Figure 3 is the broad-spectrum free radical scavenging ability of the multifunctional nanoparticle cRGD-TPNs / DC targeting abdominal aortic aneurysm in Experimental Example 2, A is the scavenging rate of ABST free radicals by cRGD-TPNs / DC at different concentrations, B is the change in color of each free radical solution with the increase of cRGD-TPNs / DC concentration; C is ·O2 - Changes in UV absorption of free radicals, D is ·O2 - Free radical scavenging rate; E is the change in UV absorption of ·NO free radical, F is the free radical scavenging rate of ·NO free radical, G is the change in UV absorption of ·OH free radical, and H is the free radical scavenging rate of ·OH free radical;

[0027] Figure 4The cell-targeted uptake of the multifunctional nanoparticle cRGD-TPNs / DC targeting abdominal aortic aneurysm in Experimental Example 3, A is fluorescence microscopy, B is flow cytometry observation of VSMC uptake of different nanoparticles, D is flow cytometry observation of RAW264.7 uptake of different nanoparticles, C is the fluorescence quantitative results of VSMC uptake of different nanoparticles, E is the fluorescence quantitative results of RAW264.7 uptake of different nanoparticles, F is the intracellular fluorescence image after VSMC and cRGD-TPNs / DC NPs incubated for different times, G is the intracellular fluorescence image after RAW264.7 and cRGD-TPNs / DC NPs incubated for different times, H and I are Western-blot analysis of MMP9 expression and grayscale quantification in different treatment groups, K and L are Western-blot analysis of MMP2 expression and grayscale quantification in different treatment groups, J is qPCR detection of MMP9 expression, and M is qPCR detection of MMP2 expression;

[0028] Figure 5 The intracellular antioxidant and anti-inflammatory properties of cRGD-TPNs / DC NPs and their induction of macrophage repolarization activity in Experimental Example 4. AD is the observation of General ROS, O2 - , ·OH / ONOO-, ·NO free radical fluorescence images, EH is the fluorescence quantitative results, I is the fluorescence microscope picture, J is the free radical level in VSMC after different treatments determined by flow cytometry, K is the quantitative result, L is the qPCR detection of TNF-a mRNA level in macrophages after different treatments, M is the qPCR detection of IL-6 mRNA level in macrophages after different treatments, N is the immunofluorescence analysis of CD206 and iNOS expression in RAW264.7 cells after different treatments; O is the qPCR detection of CD206 expression in macrophages after different treatments, P is the qPCR detection of iNOS expression in macrophages after different treatments;

[0029] Figure 6 This is a study on the anti-VSMC cell apoptosis and calcification activity of cRGD-TPNs / DC NPs in Experimental Example 5, A is the intracellular calcification staining of VSMC after different treatments taken under a microscope and a digital camera, B is the flow cytometry detection of cell apoptosis of VSMC cells after different treatments, C is the numerical quantification of apoptosis intensity, D and E are respectively the intracellular calcification staining of VSMC cells after different treatments taken under a microscope and a digital camera, F is the numerical quantification of calcification intensity, and G is the cell viability of VSMC cells after different treatments detected by CCK8;

[0030] Figure 7The in vivo targeting performance of cRGD-TPNs / DC NPs in Experimental Example 6, A is the establishment of AAA mouse model, as well as the schematic diagram of tissue distribution and therapeutic administration, B is the in vitro imaging of the aorta of normal mice and AAA mice after different treatments for 24 hours, C is the numerical quantification of fluorescence intensity, D E are in vitro imaging of the aorta and major visceral organs at different time points after AAA mice were given cRGD-TPNs-Cy5.5 NPs, and F is the fluorescence quantification diagram;

[0031] Figure 8 The in vivo efficacy of cRGD-TPNs / DC NPs in Experimental Example 7, A is the diameter of the abdominal aorta observed by digital camera and color Doppler ultrasound, B is the numerical quantification under color Doppler ultrasound measurement, C is the pathological changes of abdominal aorta tissue sections of mice in different treatment groups by HE staining, EVG detection of elastin layer damage in the aortic wall, and Alizarin red detection of vascular wall calcification deposition, and D is TUNEL detection of aortic vascular wall apoptosis;

[0032] Fig. 9 The in vivo mechanism of action of cRGD-TPNs / DC NPs in Experimental Example 8, A is Western blot detection of the expression of MMP9 and MMP2 in different treatment groups, BC is the gray value quantification of MMP9 and MMP2, D is immunohistochemical detection of the expression of MMP2 and MMP9 in abdominal aorta tissue sections in different treatment groups; EF is the levels of H2O2 and MDA in serum of different treatment groups; GH is qPCR detection of the mRNA expression levels of TNF-ɑ and IL-1β in abdominal aorta tissue of different treatment groups; I is immunofluorescence analysis of the expression of CD206 and iNOS;

[0033] Fig.10 is the in vivo safety of cRGD-TPNs / DC NPs in Experimental Example 9, A is the hemolytic assay of cRGD-TPNs / DC NPs at different concentrations, B is the weight change of mice in different treatment groups within 28 days, CF is the BUN, CR, ALT, and AST levels in the serum of mice after different treatments, and G is HE section staining of the main visceral organs of mice after different treatments;

[0034] Fig.11 The cell viability of TPNs, DC and cRGD-TPNs / DC NPs after being taken up by cells in Experimental Example 3; A is the cell viability of TPNs after being taken up by cells, B is the cell viability of DC after being taken up by cells; C is the cell viability of cRGD-TPNs / DC NPs after being taken up by cells;

[0035] Fig.12As the in vivo mechanism of action of cRGD-TPNs / DC NPs in Experimental Example 8, the expression of MMP2 / MMP9 in the vascular wall tissue of the abdominal aorta after AngⅡ treatment was analyzed by mRNA qPCR, A is the expression of MMP9 in the tissue, and B is the expression of MMP2 in the tissue. DETAILED DESCRIPTION

[0036] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0037] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and substance of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention are within the scope of the present invention.

[0038] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art; unless otherwise specified, the reagents used in the examples are commercially available.

[0039] Example 1

[0040] Preparation of multifunctional nanoparticles targeting abdominal aortic aneurysm

[0041] S1. Preparation of carrier polyphenol oxidized self-polymerized nanoparticles TPNs: 3 mL of 100 mM HEPES buffer solution with a pH of 7.4 was added to a 100 mL beaker, 25.65 mL of ultrapure water was added, 750 μL of 100 mM EGCG solution was added, and the mixture was stirred in a water bath at room temperature for 1 min to obtain a mixed solution, and then 600 μL of 100 mM MnC12 solution was added dropwise, and the mixture was placed in a constant temperature water bath at 25°C and stirred vigorously for 1 h. The reaction solution was centrifuged at 16,000 rpm for 20 min to collect the nanoparticles, and the nanoparticles were washed twice with HEPES buffer (10 mM, pH 7.4), and the precipitate was re-dissolved by ultrasonication to obtain polyphenol self-polymerized nanoparticles TPNS;

[0042] S2, modification of targeting ligand cRGD: 20 μL of 5 mM thiol-polyethylene glycol-cyclic arginine-glycine-aspartic acid (SH-PEG-cRGD) was added to the system prepared in S1 and stirred in a constant temperature water bath at 37°C for 2 h to construct cRGD-TPNs;

[0043] S3, adsorption of doxycycline DC: add 20 μL 22.5 mM doxycycline (DC) to the system prepared in S2, stir in a constant temperature water bath at 37°C for 2 h, and obtain multifunctional nanoparticles targeting abdominal aortic aneurysm cRGD-TPNs / DC;

[0044] Figure 2 A is a schematic diagram of the synthesis of cRGD-TPNs. Figure 2 F is a schematic diagram of cRGD-TPNs / DC synthesis.

[0045] Experimental Example 1

[0046] Investigation of the characteristics of nanoparticles TPNS, cRGD-TPNs and cRGD-TPNs / DC

[0047] The results are as follows Figure 2 As shown in A, after the S1 step, the color of the solution changed from colorless to dark, indicating the successful synthesis of TPNs. Compared with TPNs, the particle size of cRGD-TPNs increased slightly ( Figure 2 B), while the zeta potential decreased significantly ( Figure 2 C), indicating that SH-PEG-cRGD was successfully bonded to the surface of the nanoparticles.

[0048] The bonding rate of SH-PEG-cRGD was quantitatively characterized by a thiol kit. After treatment, cRGD-TPNs had a typical thiol absorption peak at 380 nm ( Figure 2 D), based on which the bonded amount of SH-PEG-cRGD was calculated to be 0.296 μmol / ml.

[0049] Through transmission electron microscopy, cRGD-TPNs are spherical nanoparticles with uniform particle size, and the average particle size is about 200nm ( Figure 2 E). Further elemental analysis revealed that the structure is mainly composed of C and O, which is consistent with the chemical structure of EGCG monomer. In addition, a small amount of residual Mn element can be observed, which may be due to the presence of Mn 2+ Surface adsorption caused by strong coordination with -OH in the structure.

[0050] After adsorption of DC, the DLS particle size of the nanoparticles increased slightly ( Figure 2 B), and a significant decrease in the surface negative charge was observed ( Figure 2 C), which is due to the positive charge of DC. Through the quantitative characterization of UV-visible spectroscopy, it was found that the nanoparticles have a strong adsorption effect on DC. When the dosage is 500μg / ml, the encapsulation rate can still reach 81% ( Figure 2 H). Observation under transmission electron microscopy showed that there was no obvious change or aggregation in the structure of the nanoparticles after adsorption of DC ( Figure 2 G). Structural element analysis revealed that cRGD-TPNs / DC showed obvious enrichment of N, further confirming the successful adsorption of DC ( Figure 2 G).

[0051] The nanoparticles were incubated at 37°C under conditions such as culture medium, PBS, saline, FBS, H2O, and HEPES, and the DLS particle size was dynamically measured. It was found that cRGD-TPNs / DC remained stable within 48 hours, and the particle size did not change significantly ( Figure 2 I), indicating that the nanoparticles have good colloidal stability in various physiological matrices.

[0052] Subsequently, the in vitro release behavior of the drug was measured. Under the buffer condition of pH 7.4, cRGD-TPNs / DC showed typical sustained-release characteristics, with a cumulative release of 16% ( Figure 2 J). This indicates that the drug can be stably adsorbed on the surface of the nanoparticles during its circulation in the body, thus reducing premature drug leakage.

[0053] In the AAA microenvironment, there is a high concentration of H2O2 locally due to oxidative stress. Therefore, different concentrations of H2O2 were added to simulate the AAA microenvironment. The results showed that the release rate of the drug increased significantly after the addition of H2O2, confirming the stimuli-responsive drug release characteristics of the nanoparticles ( Figure 2 J). Therefore, cRGD-TPNs / DC can stably adsorb drugs in the blood circulation and quickly release drugs after reaching the AAA site, thereby extending the half-life of drugs, reducing the toxic side effects of drugs, and better exerting therapeutic effects.

[0054] Experimental Example 2

[0055] Investigating the broad-spectrum free radical scavenging ability of multifunctional nanoparticles cRGD-TPNs / DC targeting abdominal aortic aneurysm

[0056] The ABST detection kit was used to evaluate its ability to scavenge total RONS. Under the oxidative conditions of (NH4)2S2O8, ABST can produce stable free radicals and exhibit an ultraviolet absorption peak at 732nm.

[0057] The results showed that with the increase of cRGD-TPNs / DC NPs concentration, the UV absorption gradually decreased, from which the free radical scavenging rate ( Figure 3 A) Overall, the free radical scavenging ability of cRGD-TPNs / DC NPs is linearly correlated with the concentration. When the concentration reaches 125 μg / ml, the scavenging ability can reach as high as 81.89%.

[0058] Further investigation of the nanoparticles' broad-spectrum scavenging ability against other physiologically relevant free radicals, including ·OH, ·O2 - With the treatment of the kit, different types of RONS solutions were purple. With the increase of cRGD-TPNs / DC NPs concentration, the color of the solution gradually faded ( Figure 3B). When the concentration of nanoparticles reached 125 μg / ml, the color of the solution became significantly lighter. In order to quantify the free radical scavenging ability, the UV-visible absorption spectra of different free radicals were measured. The results showed that with the increase of cRGD-TPNs / DC NPs concentration, the UV absorption gradually decreased ( Figure 3 C, 3E, 3G). When the concentration of cRGD-TPNs / DC NPs reached 125 μg / ml, O2 - The removal rates of NO and ·OH were 54%, 67% and 83% respectively. Figure 3 D, 3F, 3H).

[0059] In summary, cRGD-TPNs / DC NPs TPNs encapsulated with DC still have a broad spectrum of free radical scavenging ability.

[0060] Experimental Example 3

[0061] Investigating the cell-targeted uptake of multifunctional nanoparticles cRGD-TPNs / DC targeting abdominal aortic aneurysm and its inhibition of MMPs activity in cells

[0062] (1) Cell-targeted uptake characteristics of cRGD-TPNs / DC

[0063] VSMC cells and RAW264.7 cells were selected as experimental cells. The nanosystem was fluorescently labeled with FITC, and the cell nucleus was stained with DAPI. Confocal microscopy showed that the intracellular signal of TPNs / DC NPs was weak ( Figure 4 A), which may be due to the fact that PEG-modified and negatively charged nanoparticles are not conducive to cell endocytosis. However, the fluorescence intensity of cRGD-TPNs / DC NPs modified with cRGD increased significantly. This may be due to the high expression of cRGD receptors (integrin αν3β receptors) on the surface of VSMC cells, which can mediate the cell uptake of NPs. To confirm this, VSMCs were pretreated with free SH-PEG-cRGD, and the fluorescence signal was significantly weakened, clarifying the important role of cRGD and its receptor recognition in nanoparticle endocytosis.

[0064] The same reverse method was used to evaluate the uptake of nanoparticles by RAW264.7. The uptake of cRGD-TPNs / DC and TPNs / DC NPs by unactivated RAW264.7 was weak ( Figure 4A). However, after polarization by LPS treatment, RAW264.7 cells selectively enhanced the uptake of cRGD-TPNs / DC NPs. This difference was due to the fact that LPS induction could increase the expression of integrin αν3β receptor on the surface of macrophage membranes, which promoted the uptake of TPNs-PEG-cRGD / DC NPs by cells through the binding of integrin αν3β receptor to ligands on the surface of TPNs-PEG-cRGD / DC NPs. The cells were pretreated with free SH-PEG-cRGD, and the fluorescence signal was weakened again.

[0065] Flow cytometry was used to quantitatively analyze the fluorescence intensity of cellular uptake and found that VSMCs could significantly enhance the uptake of cRGD-TPNs / DC NPs, but this enhancement of fluorescence signal could be blocked by free SH-PEG-cRGD ( Figure 4 B, C). The uptake capacity of polarized macrophages for cRGD-TPNs / DC NPs was 4.9 times that of macrophages cultured under normal conditions ( Figure 4 D, E). Similarly, this enhanced uptake signal can also be blocked by SH-PEG-cRGD. Overall, the results of flow cytometry are highly consistent with the results of confocal microscopy, confirming that cRGD modification can enhance the targeting of nanoparticles to VSMCs.

[0066] The kinetics of nanoparticle uptake by cells was evaluated by observing the intracellular fluorescence signals at different time points. The results showed that with the increase of time, VSMC ( Figure 4 F) and RAW264.7( Figure 4 G) The intracellular green fluorescence gradually increased, indicating that the uptake capacity has a certain time dependence. The cytotoxicity of the nanoparticles after uptake was determined by MTT. The results showed that the cRGD-modified TPNs carrier had low toxicity. After incubation at a concentration of 150μg / ml for 24h, the cell viability was still higher than 80% ( Fig.11 ). Free DCs can cause certain cytotoxicity at concentrations higher than 20 μg / ml. However, when DCs are encapsulated in nanoparticle structures, their toxicity is reduced, which is due to the sustained release of the drug in the nanoparticles.

[0067] (2) cRGD-TPNs / DC inhibits MMPs activity in cells

[0068] Western blot was used to detect the expression levels of intracellular MMP9 and MMP2 proteins. After LPS treatment, MMP9 and MMP2 in VSMC cells were significantly upregulated ( Figure 4H, K), indicating the activation of macrophages. The expression and secretion of MMP9 and MMP2 can lead to matrix degradation and promote the progression of AAA. cRGD-TPNs / DC NPs treatment can significantly inhibit the expression of MMP9 and MMP2, demonstrating the therapeutic potential of nanoparticles for AAA.

[0069] It is worth noting that cRGD-TPNs NPs without DC also have a certain ability to regulate MMPs, which may be due to the powerful anti-inflammatory and antioxidant effects of TPNs. Therefore, DC can achieve functional synergy with TPNs and jointly play a role in regulating MMPs. Further grayscale quantification of protein expression ( Figure 4 I, L), and the mRNA levels were determined by qPCR ( Figure 4 J, M). The above quantitative results all confirmed the effective regulatory ability of cRGD-TPNs / DC NPs on MMPs.

[0070] Experimental Example 4

[0071] Investigation of the intracellular antioxidant and anti-inflammatory properties of cRGD-TPNs / DC NPs and their ability to induce macrophage repolarization

[0072] LPS was used to activate RAW264.7 cells, and the intensity of intracellular general ROS was detected using a free radical fluorescent probe. The results showed that after LPS induction, obvious fluorescent signals appeared in the cells ( Figure 5 A). However, after adding cRGD-TPNs / DCNPs and cRGD-TPNs NPs, the fluorescence signal was significantly weakened. This indicates the free radical scavenging activity of the nanoparticles. To further explore the activity of scavenging a wide range of free radicals in cells, we used 2′, 7′-dichlorodihydrofluorescein diacetate (DCFH-DA), dihydroethidium (DHE) and hydroxyphenylfluorescein (HPF) to scavenge hydrogen peroxide, O2 - Fluorescence microscopy showed that cRGD-TPNs / DC NPs and cRGD-TPNs NPs could reduce the fluorescence to the background level ( Figure 5 AD). Flow cytometry was used to quantify the fluorescence intensity, and the results showed a significant ROS elimination effect ( Figure 5 EH).

[0073] Using the same method, we determined the free radical scavenging activity of nanoparticles in VSMC cells. H2O2 was used to induce an increase in the level of intracellular free radicals, and dihydroethidium (DHE) fluorescent probe was used for fluorescence tracing. Fluorescence microscopy was used to observe ( Figure 5I) and flow cytometry detection (5J-K) confirmed that the nanoparticles can significantly reduce the intracellular fluorescence signal. In general, cRGD-TPNs / DC NPs can widely scavenge various types of oxidative free radicals in different cells, demonstrating the ability of nanoparticles to effectively protect cells from oxidative damage.

[0074] The expression levels of representative inflammatory factors were measured, including TNF-ɑ and IL-1β, which play an important role in inducing macrophage infiltration of the aortic wall. By qRCR assay, it was found that the secretion of inflammatory factors in LPS-activated macrophages was significantly upregulated ( Figure 5 L, M), but TNF-ɑ and IL-1β can be reduced to normal levels after nanoparticle treatment. In comparison, cRGD-TPNs / DC NPs have stronger anti-inflammatory ability than cRGD-TPNs NPs, especially for IL-1β, which is mainly attributed to the anti-inflammatory effect of DC. Therefore, TPNs loaded with DC have a stronger inhibitory effect on inflammation.

[0075] In view of the powerful antioxidant and anti-inflammatory effects of cRGD-TPNs / DC NPs, we further studied its regulatory effect on macrophage phenotype. By immunofluorescence assay, we found that the expression of M1 marker iNOS was significantly upregulated after LPS stimulation, while the expression of M2 marker CD206 was reduced ( Figure 5 N), indicating that LPS successfully stimulated M1 polarization. After treatment with nanoparticles, the fluorescence signal of iNOS was significantly weakened, while the fluorescence signal of CD206 increased. In order to more accurately determine the polarization state of macrophages, we used qPCR experiments to detect the expression of iNOS and CD206 mRNA in different treatment groups. The results were consistent with the image trend of the fluorescence microscope ( Figure 5 O, P). Compared with cRGD-TPNs NPs, cRGD-TPNs / DC NPs have stronger regulatory effects on iNOS and CD206. Therefore, TPNs nanocarriers can synergize with DC to promote the M1-TO-M2 repolarization of macrophages.

[0076] Experimental Example 5

[0077] Study on the anti-VSMC apoptosis and calcification activity of cRGD-TPNs / DC NPs

[0078] VSMC apoptosis and calcification are important factors in the damage of the abdominal aorta vascular wall. H2O2 induction can simulate the AAA disease microenvironment and induce cell apoptosis. Using flow cytometry quantitative determination, it can be observed that the number of apoptotic cells increased significantly after H2O2 treatment ( Figure 6A). However, after nanoparticle treatment, the level of cell apoptosis was significantly reduced. Similarly, TPNs nanoparticles can synergize with DCs, so cRGD-TPNs / DC NPs have the strongest anti-apoptotic ability, reducing the number of apoptotic cells by 5 times ( Figure 6 B). CCK8 experiments further confirmed the protective effect of nanoparticles against H2O2-induced cell apoptosis ( Figure 6 C).

[0079] To study the anti-calcification effect of nanoparticles, we used Ca / Pi to induce intracellular calcification of VSMCs and marked the calcification precipitates by Alizarin red staining ( Figure 6 D, E, F). After treatment with nanoparticles, the color precipitation was significantly weakened, confirming the anti-calcification effect of the nanoparticles. This is mainly attributed to the free radical scavenging activity of the nanoparticles, which effectively improves oxidative stress and inhibits intracellular calcification levels. Similarly, due to the encapsulation of DC, cRGD-TPNs / DC NPs have stronger anti-calcification activity than cRGD-TPNs NPs. CCK8 assay demonstrated that cRGD-TPNs / DC showed the best cell protection effect in this model ( Figure 6 G).

[0080] In summary, the combination of TPNs and DCs can synergistically exert anti-apoptosis and calcification effects, thereby protecting the abdominal aorta from vascular wall damage.

[0081] Experimental Example 6

[0082] Investigation of the in vivo targeting performance of cRGD-TPNs / DC NPs

[0083] The AAA model was established by continuously pumping AngⅡ (1 μg / kg / min) into ApoE- / - mice for 28 days. Figure 7 A), in order to verify the in vivo targeting ability of NPs to AAA mice, Cy5.5-labeled nanoparticles were intravenously injected on the 28th day of modeling, and normal mice were used as controls. The aorta was stripped 24 hours after administration for fluorescence imaging. cRGD-TPNs NPs had no obvious fluorescence in the abdominal aorta vascular wall of normal mice, but had obvious fluorescence signals in the wall lesions of AAA mice ( Figure 7 B). In comparison, no obvious fluorescence signal was observed for TPNs NPs at the AAA site, suggesting that the upregulation of integrin αν3β receptor at the AAA site may mediate the retention of cRGD-modified nanoparticles at the lesion site.

[0084] The AAA mice were pretreated by injecting free SH-PEG-cRGD into the tail vein, and it was found that the enrichment of cRGD-TPNs in the AAA site could be blocked under this condition. The fluorescence intensity of the AAA aorta vessel wall was quantitatively analyzed, and it was found that the fluorescence signal of the cRGD-TPNs group was 5 times that of TPNs ( Figure 7 C), and this enhancement effect could be completely blocked by pretreatment with SH-PEG-cRGD.

[0085] To explore the persistence of enrichment, we detected the fluorescence intensity of the aorta wall and viscera of AAA mice at different time points. 24 hours after administration, a high fluorescence intensity could still be observed in the lesion site of the abdominal aorta ( Figure 7 D), indicating that the nanoparticles have a long retention time in this part. At the same time, the liver and kidney tissues also have strong fluorescence signals at 24h, indicating the long circulation of nanoparticles ( Figure 7 E). At 48 hours after administration, the fluorescence in the aortic lesion and major organs was significantly reduced ( Figure 7 DF), indicating that the nanoparticles can be slowly metabolized and cleared. The above results show that SH-PEG-cRGD modification can make the nanoparticles have long circulation characteristics and can actively target and enrich in AAA lesion tissues.

[0086] Experimental Example 7

[0087] Investigating the in vivo efficacy of cRGD-TPNs / DC NPs

[0088] Treatment process Figure 7 As shown in A, the drug was administered once every two days during the modeling process. The aortic diameter was measured by ultrasound, and then the mice were euthanized and the AAA was isolated for further study. Compared with the normal group and the modeling control group with daily infusion of Saline, the diameter of the abdominal aorta in the AngⅡ group was significantly enlarged ( Figure 8 A), indicating the successful construction of the disease model. After treatment with free DC and cRGD-TPNs, the diameter of AAA in mice was reduced ( Figure 8 B) Among the treatment groups, cRGD-TPNs / DC NPs had the most significant effect. For further intuitive observation, the aorta was stripped and measured, and the quantitative treatment effect was ranked as cRGD-TPNs / DC NPs>cRGD-TPNs>DC.

[0089] To further evaluate the protective effect of nanoparticles on pathological damage of AAA vascular wall, systematic pathological characterization was performed, including H&E staining, EVG staining and Alizarin red staining ( Figure 8C). Compared with the control group and saline group, the aortic wall of the model group still had a certain degree of damage after DC treatment, with rupture and damage of the elastic plate and obvious calcification. After nanoparticle treatment, the damage to the aortic wall was significantly alleviated, elastin was retained, and calcification was significantly reduced. Similarly, cRGD-TPNs / DC NPs showed the best therapeutic effect. TUNEL staining was used to verify the apoptosis of the abdominal aorta vascular wall, further confirming the anti-apoptotic activity of the nanoparticles in vivo ( Figure 8 D).

[0090] The above results all confirmed the good anti-AAA efficacy of cRGD-TPNs / DC NPs in vivo.

[0091] Experimental Example 8

[0092] Investigation of the in vivo mechanism of action of cRGD-TPNs / DC NPs

[0093] After clarifying the efficacy of cRGD-TPNs / DC NPs, we further explored its mechanism of action. After AngⅡ treatment, the expression levels of MMP2 and MMP9 proteins in the abdominal aorta vascular wall tissue were significantly upregulated ( Fig. 9 A), which is consistent with the pathological changes of AAA. Free DC slightly alleviated the upregulation of MMP2 and MMP9. In comparison, nanoparticles had more obvious activity, among which cRGD-TPNs / DC NPs had the best effect. By gray protein quantification ( Fig. 9 B, C), further confirmed this trend, indicating that nanoparticles and DCs have a synergistic regulatory effect on MMPs in vivo. Fig. 9 D) and mRNA qPCR ( Fig.12 ) analyzed the expression levels of MMP2 / MMP9, and the results were consistent with the above.

[0094] Considering the ROS scavenging and inflammation-inhibiting activities of nanoparticles, we measured the representative oxidative stress markers H2O2 and MDA ( Fig. 9 E, F), and the expression levels of inflammatory factors TNF-ɑ and IL-1β in tissues ( Fig. 9 G, H). After AngⅡ treatment, the levels of oxidative stress and inflammatory factors in mice were significantly upregulated. However, under cRGD-TPNs / DCNPs treatment, these indicators were restored to normal levels.

[0095] Subsequently, immunofluorescence staining of macrophage markers CD206 and iNOS was performed to further explore the phenotypic changes of macrophages in AAA vascular wall lesions. The fluorescence of CD206 in the abdominal aorta vascular wall of the model group was significantly stronger than that of the control group, while iNOS showed an opposite trend, which was due to the M1 polarization of macrophages under pathological conditions. However, through the treatment of cRGD-TPNs / DC NPs, both CD206 and iNOS returned to normal levels ( Fig. 9 I). The above results confirmed that cRGD-TPNs / DC NPs still have the activities of regulating MMPs levels, anti-inflammatory, antioxidant and inducing macrophage repolarization in vivo, achieving the treatment of AAA through multiple mechanisms.

[0096] Experimental Example 9

[0097] Investigating the in vivo safety of cRGD-TPNs / DC NPs

[0098] The in vivo safety of nanomedicines is an important indicator for evaluating their potential for clinical transformation. To this end, we systematically evaluated the biosafety of cRGD-TPNs / DC NPs. The hemolysis rates of cRGD-TPNs / DC NPs at different concentrations were all lower than 5% ( Fig.10 A), demonstrating its good blood compatibility. During the treatment period, all mice had normal diet, water intake and activity, and there was no significant difference in weight gain between the groups ( Fig.10 B). By testing the serum biochemical indicators of mice, it was found that BUN, CR, AST, and ALT all showed abnormal increases after free DC treatment ( Fig.10 CF), suggesting that DC can cause acute liver and kidney toxicity. This is also the bottleneck of DC clinical transformation. However, cRGD-TPNs / DC NPs did not show relevant toxicity, which may be due to the sustained release of drugs mediated by nanocarriers, which reduced the toxicity of drugs. To further confirm, hematoxylin and eosin staining of the main organs of mice also observed liver and kidney damage caused by DC treatment ( Fig.10 G). However, at the same dose and treatment mode, no cRGD-TPNs / DC NPs-related toxicity was observed, which once again demonstrated that nanoparticle encapsulation can effectively reduce the systemic toxic side effects of DCs and the biosafety of nanoparticles.

[0099] The above is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments. For those skilled in the art, improvements and changes obtained without departing from the technical concept of the present invention should also be regarded as the protection scope of the present invention.

Claims

1. A multifunctional nanoparticle targeting abdominal aortic aneurysm, characterized in that: The nanoparticles include polyphenol oxidation self-polymerized nanoparticles, doxycycline and targeting ligand cRGD. The polyphenol oxidation self-polymerized nanoparticles are used as carriers, the targeting ligand cRGD is firstly modified on the surface, and then doxycycline is adsorbed on the surface.

2. A method for preparing multifunctional nanoparticles targeting abdominal aortic aneurysm as claimed in claim 1, characterized in that: The following steps are involved: S1. Preparation of carrier polyphenol oxidized self-polymerized nanoparticles: dissolving epigallocatechin gallate in a buffer solution of pH 7.4-8.5, stirring in a water bath at room temperature to obtain a mixed solution of epigallocatechin gallate, then dropping a divalent metal manganese ion solution, keeping the mixture in a water bath at a constant temperature, stirring vigorously, and then centrifuging to collect the precipitate, washing the precipitate with a buffer solution, and re-dissolving the precipitate by ultrasonication to obtain polyphenol oxidized self-polymerized nanoparticles; S2, modifying the targeting ligand cRGD: adding thiol-polyethylene glycol-cyclic arginine-glycine-aspartic acid to the system prepared in S1 and stirring in a constant temperature water bath to construct the targeting ligand cRGD-polyphenol oxidized self-polymerized nanoparticles; S3. Adsorption of doxycycline: Add doxycycline to the system prepared in S2 and stir in a constant temperature water bath to obtain multifunctional nanoparticles targeting abdominal aortic aneurysm.

3. The preparation method according to claim 2, characterized in that: The buffer in step S1 is HEPES buffer, and the final concentration of the HEPES buffer is 10-15 mM; the stirring time in a water bath at room temperature is 1 min, the centrifugal speed is 16,000 rpm, and the centrifugal time is 20 min.

4. The preparation method according to claim 2, characterized in that: In the step S1, the molar ratio of epigallocatechin gallate to divalent metal manganese ion is 1:5 to 5:

1.

5. The preparation method according to claim 2, characterized in that: In step S1, the metal manganese ion solution is a MnCl2 solution, the final concentration of the metal manganese ions after dropwise addition is 0.5-12.5 mM, the temperature of the constant temperature water bath is 25° C.-35° C., and the time of the vigorous stirring is 0.5-12 h.

6. The preparation method according to claim 2, characterized in that: The molar ratio of the thiol-polyethylene glycol-cyclic arginine-glycine-aspartic acid to doxycycline is 1:4.

5.

7. The preparation method according to claim 2, characterized in that: In step S2, the stirring temperature of the constant temperature water bath is 37° C., and the stirring time of the constant temperature water bath is 2 h. In step S3, the stirring temperature of the constant temperature water bath is 37° C., and the stirring time of the constant temperature water bath is 2 h.

8. Use of the multifunctional nanoparticle targeting abdominal aortic aneurysm as claimed in claim 1 or the multifunctional nanoparticle targeting abdominal aortic aneurysm prepared by the preparation method according to any one of claims 2 to 7 in a drug for inhibiting the progression of abdominal aortic aneurysm.

Citation Information

Patent Citations

  • Polyphenol self-polymerization nanoparticles as well as preparation method and application thereof

    CN116173006A

  • Nanoparticles for targeted therapy of thrombotic diseases as well as preparation method and application of nanoparticles

    CN116370434A

  • TPNs-siRNA nano preparation as well as preparation method and application thereof

    CN118356412A

  • Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle

    US20090214654A1

  • Scavenger receptor-a targeted drug carrier, and preparation method and application thereof

    WO2021121082A1